BioShield II Patent Extensions Will Increase Drug Costs, GPhA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Generic Pharmaceuticals Association supports the overall goals of the bill but claims product exclusivity extensions will needlessly inflate pharmaceutical costs. The association will testify before the Oct. 6 joint Senate Judiciary/Health Committee hearing.